Developer docs
API playgroundTry for free, no card

Search company profiles

Signpath Pharma

Full company profile

uuid00078cv

Namestring
Signpath Pharma
Legal namestring
Signpath Pharma, Inc.
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Signpath Pharma is a clinical-stage biotechnology company headquartered in Sandy, Utah, founded in 2007 by Bruce Meyers. The company operates two proprietary technology platforms: LipoCurc, a liposomal curcumin formulation for cancer treatment, and the CorreQT platform, which develops cardiac-safe versions of existing drugs by eliminating drug-induced arrhythmia and cardiac muscle damage. The company has no commercial revenue and operates on prior capital raised through equity funding rounds.

LipoCurc, the lead clinical asset, is a proprietary intravenous liposomal curcumin formulation licensed exclusively from MD Anderson Cancer Center. The product achieves blood curcumin levels more than 1,000 times higher than oral dosing without cardiotoxicity. It has completed Phase 1a/1b trials in 70 human subjects demonstrating no cardiac toxicity and preliminary efficacy in heavily pre-treated cancer patients. A Phase 2 trial in first-line glioblastoma treatment is enrolling at Johns Hopkins University Hospital, with additional sites planned. The asset received FDA Orphan Drug Designation in 2025 and the company has submitted Fast Track and CNPV designation requests. Additional mesothelioma trials are being prepared, and working relationships extend into Canada, Europe, and Asia.

The CorreQT platform, led by compound SPP4040, is a lipid-based oral drug positioned to extend into antibiotics, antipsychotics, and antihistamines beyond its initial oncology focus. The intellectual property estate comprises more than 15 issued US patents with corresponding international filings covering cardiac arrhythmia, cardiomyopathy, and cytokine storm, with protection running through at least 2037, supported by a publication record of 63+ papers. As a micro-cap company with 1-10 employees and approximately $7.3 million in total disclosed funding across three rounds between 2011 and 2016, Signpath's business model is contingent on future capital raises to advance its pipeline toward potential FDA approval, licensing transactions, or acquisition. The company trades on the OTC pink market under ticker SGTH.

Short descriptiontext

Signpath Pharma is a clinical-stage biotechnology company developing LipoCurc, a proprietary liposomal curcumin therapy in Phase 2 trials for glioblastoma, and the CorreQT platform for creating cardiac-safe versions of existing drugs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSandy, United States
HQ citystring
Sandy
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liposomal curcumin formulation, cardiac safety drugs, glioblastoma therapeutics, cancer supportive care, clinical stage biotechnology
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Oncology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1LipoCurc (Liposomal Curcumin)
TypeOne Time License
Description

Revenue from proprietary liposomal curcumin product for cancer treatment, currently in Phase 2 clinical trials for glioblastoma and being prepared for mesothelioma trials.

signpathpharma.com
2CorreQT Platform Compounds
TypeOne Time License
Description

Revenue from cardiac-safe drug formulations (SPP4040 and other compounds) addressing the cardio-protective agent market for cancer supportive care.

signpathpharma.com
3Cancer Supportive Care
TypeOne Time License
Description

Cardio-protective agent intended for use alongside chemotherapy agents, positioned similar to Amgen's Neupogen model.

signpathpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LipoCurc™
Description

Proprietary liposomal formulation of curcumin administered intravenously for cancer treatment, particularly glioblastoma and mesothelioma.

signpathpharma.com
+1 more record
Core offering1 text field

Signpath Pharma is a clinical-stage pharmaceutical company that develops proprietary drug products built around two technology platforms. The first is LipoCurc, an intravenously administered liposomal curcumin formulation for cancer treatment (Phase 2 for glioblastoma). The second is the CorreQT platform, which creates cardiac-safe versions of existing drugs; its lead compound SPP4040 is an oral lipid-based drug designed to eliminate chemotherapy-induced cardiac arrhythmia and cardiac muscle damage.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 1 trials: No cardiac toxicity observed in 70 human subjects
+1 more record
Product overview1 text field

Signpath Pharma is a clinical-stage pharmaceutical company with two key product programs. The primary clinical product is LipoCurc, a proprietary liposomal curcumin formulation administered intravenously for cancer treatment, which has completed Phase 1a/1b trials and is now in Phase 2 for glioblastoma. The second is the CorreQT technology platform, which uses a patented approach to create heart-safe versions of existing drugs; the lead compound from this platform is SPP4040, an oral lipid-based drug in development for cardiac protection during chemotherapy.

Product and service2 records
1LipoCurc
CategoryCancer Therapeutics / Oncology Drug
Description

LipoCurc is a proprietary liposomal formulation of curcumin administered intravenously for the treatment of cancer. It achieves curcumin blood levels over 1000 times greater than standard oral curcumin without cardiotoxicity. It has completed Phase 1a and 1b trials in 70 human subjects and is currently enrolling in a Phase 2 trial for first-line treatment of glioblastoma at Johns Hopkins University Hospital. It is also being prepared for mesothelioma trials.

2CorreQT Platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

LipoCurc was developed by researchers at M.D. Anderson Cancer Center and exclusively licensed to Signpath. This foundational research partnership established the company's lead product.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase 2 clinical trial site for first-line treatment of glioblastoma. Signpath is working to expand the number of clinical sites.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Working relationships with labs, hospitals, and other companies in Canada, Europe, the U.S., and Asia for research and development activities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing MDNA55 for recurrent glioblastoma. Similar stage, similar indication focus, and similar small-cap biotech profile with novel mechanism approaches to CNS tumors.

TypeEmerging player
Description

Clinical-stage biotech that has pioneered novel oncology mechanisms (imetelstat) with similar small-cap, late-clinical-stage profile and dependence on a single platform technology.

3Bristol-Myers Squibb
TypeBroad incumbent
Description

Large oncology incumbent with checkpoint inhibitors (Opdivo) targeting PD-1/PD-L1 pathways relevant to LipoCurc's mechanism. Represents the broader immunotherapy landscape where LipoCurc's immunomodulatory claims would compete.

TypeDirect peer
Description

Clinical-stage company developing MB-101 (CAR-T) for glioblastoma. Directly comparable as a small-cap clinical-stage company pursuing novel therapies in glioblastoma with similar trial-stage risk profile.

TypeDirect peer
Description

Australia-based clinical-stage oncology company developing paxalisib for glioblastoma. Directly comparable to Signpath as a small-cap, clinical-stage biotech focused on novel glioblastoma therapeutics with similar regulatory pathway considerations.

TypeOthers
Description

Large biopharmaceutical company explicitly cited by Signpath as the model for cancer supportive care (Neupogen). Represents the commercial reference for the supportive-care positioning of Signpath's CorreQT platform.

TypeEmerging player
Description

Clinical-stage biotech with DNA medicines including INO-5401 for glioblastoma. Comparable as a small-cap clinical-stage oncology company pursuing novel mechanisms in the same indication.

TypeDirect peer
Description

Clinical-stage oncology company developing VAL-083 (dianhydrogalactitol) for glioblastoma. Comparable small-cap structure with similar Phase 2/3 development stage and indication focus.

TypeBroad incumbent
Description

Commercial-stage company with FDA-approved Tumor Treating Fields (Optune) for glioblastoma. Represents the established standard-of-care that LipoCurc would compete against in the same indication.

TypeEmerging player
Description

Clinical-stage oncology biotech developing small-molecule targeted therapies. Similar small-cap clinical-stage profile pursuing novel oncology mechanisms across multiple indications.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Signpath Pharma

Clinical-stage Oncology Pharmaceuticalssignpathpharma.com

Signpath Pharma is a clinical-stage biotechnology company developing LipoCurc, a proprietary liposomal curcumin therapy in Phase 2 trials for glioblastoma, and the CorreQT platform for creating cardiac-safe versions of existing drugs.

What Signpath Pharma does

Signpath Pharma is a clinical-stage biotechnology company headquartered in Sandy, Utah, founded in 2007 by Bruce Meyers. The company operates two proprietary technology platforms: LipoCurc, a liposomal curcumin formulation for cancer treatment, and the CorreQT platform, which develops cardiac-safe versions of existing drugs by eliminating drug-induced arrhythmia and cardiac muscle damage. The company has no commercial revenue and operates on prior capital raised through equity funding rounds.

LipoCurc, the lead clinical asset, is a proprietary intravenous liposomal curcumin formulation licensed exclusively from MD Anderson Cancer Center. The product achieves blood curcumin levels more than 1,000 times higher than oral dosing without cardiotoxicity. It has completed Phase 1a/1b trials in 70 human subjects demonstrating no cardiac toxicity and preliminary efficacy in heavily pre-treated cancer patients. A Phase 2 trial in first-line glioblastoma treatment is enrolling at Johns Hopkins University Hospital, with additional sites planned. The asset received FDA Orphan Drug Designation in 2025 and the company has submitted Fast Track and CNPV designation requests. Additional mesothelioma trials are being prepared, and working relationships extend into Canada, Europe, and Asia.

The CorreQT platform, led by compound SPP4040, is a lipid-based oral drug positioned to extend into antibiotics, antipsychotics, and antihistamines beyond its initial oncology focus. The intellectual property estate comprises more than 15 issued US patents with corresponding international filings covering cardiac arrhythmia, cardiomyopathy, and cytokine storm, with protection running through at least 2037, supported by a publication record of 63+ papers. As a micro-cap company with 1-10 employees and approximately $7.3 million in total disclosed funding across three rounds between 2011 and 2016, Signpath's business model is contingent on future capital raises to advance its pipeline toward potential FDA approval, licensing transactions, or acquisition. The company trades on the OTC pink market under ticker SGTH.

Signpath Pharma firmographics

Firmographics
Name
Signpath Pharma
Legal name
Signpath Pharma, Inc.
Website
https://signpathpharma.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Signpath Pharma is a clinical-stage biotechnology company developing LipoCurc, a proprietary liposomal curcumin therapy in Phase 2 trials for glioblastoma, and the CorreQT platform for creating cardiac-safe versions of existing drugs.
Ownership category
akta.pro rank

Signpath Pharma industry classification

Industry
Product category
Clinical-stage Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Liposomal curcumin formulation
  • Cardiac safety drugs
  • Glioblastoma therapeutics
  • Cancer supportive care
  • Clinical stage biotechnology

Where Signpath Pharma is headquartered

Location

Headquarters

HQ city
Sandy
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Signpath Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. LipoCurc (Liposomal Curcumin): Revenue from proprietary liposomal curcumin product for cancer treatment, currently in Phase 2 clinical trials for glioblastoma and being prepared for mesothelioma trials.
  2. CorreQT Platform Compounds: Revenue from cardiac-safe drug formulations (SPP4040 and other compounds) addressing the cardio-protective agent market for cancer supportive care.
  3. Cancer Supportive Care: Cardio-protective agent intended for use alongside chemotherapy agents, positioned similar to Amgen's Neupogen model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Signpath Pharma product offering

Product offering

Core offering

Signpath Pharma is a clinical-stage pharmaceutical company that develops proprietary drug products built around two technology platforms. The first is LipoCurc, an intravenously administered liposomal curcumin formulation for cancer treatment (Phase 2 for glioblastoma). The second is the CorreQT platform, which creates cardiac-safe versions of existing drugs; its lead compound SPP4040 is an oral lipid-based drug designed to eliminate chemotherapy-induced cardiac arrhythmia and cardiac muscle damage.

Product overview

Signpath Pharma is a clinical-stage pharmaceutical company with two key product programs. The primary clinical product is LipoCurc, a proprietary liposomal curcumin formulation administered intravenously for cancer treatment, which has completed Phase 1a/1b trials and is now in Phase 2 for glioblastoma. The second is the CorreQT technology platform, which uses a patented approach to create heart-safe versions of existing drugs; the lead compound from this platform is SPP4040, an oral lipid-based drug in development for cardiac protection during chemotherapy.

Differentiator

Problem solved

Functional benefit

Brands

  • LipoCurc™: Proprietary liposomal formulation of curcumin administered intravenously for cancer treatment, particularly glioblastoma and mesothelioma.
  • CorreQT

Products and services

  • LipoCurc LipoCurc is a proprietary liposomal formulation of curcumin administered intravenously for the treatment of cancer. It achieves curcumin blood levels over 1000 times greater than standard oral curcumin without cardiotoxicity. It has completed Phase 1a and 1b trials in 70 human subjects and is currently enrolling in a Phase 2 trial for first-line treatment of glioblastoma at Johns Hopkins University Hospital. It is also being prepared for mesothelioma trials.
  • CorreQT Platform

Quantifiable outcome

  • Phase 1 trials: No cardiac toxicity observed in 70 human subjects
  • +1 more outcomes

Companies that use Signpath Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Signpath Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Signpath Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • M.D. Anderson Cancer CentercoreStrategic or Co-development PartnerLipoCurc was developed by researchers at M.D. Anderson Cancer Center and exclusively licensed to Signpath. This foundational research partnership established the company's lead product.
  • Johns Hopkins University HospitalcoreStrategic or Co-development PartnerPhase 2 clinical trial site for first-line treatment of glioblastoma. Signpath is working to expand the number of clinical sites.
  • International Research PartnersminorStrategic or Co-development PartnerWorking relationships with labs, hospitals, and other companies in Canada, Europe, the U.S., and Asia for research and development activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Signpath Pharma competitors and assessment

Company assessment

Direct peers

  • Medicenna Therapeutics: Clinical-stage biotech developing MDNA55 for recurrent glioblastoma. Similar stage, similar indication focus, and similar small-cap biotech profile with novel mechanism approaches to CNS tumors.
  • Mustang Bio: Clinical-stage company developing MB-101 (CAR-T) for glioblastoma. Directly comparable as a small-cap clinical-stage company pursuing novel therapies in glioblastoma with similar trial-stage risk profile.
  • Kazia Therapeutics: Australia-based clinical-stage oncology company developing paxalisib for glioblastoma. Directly comparable to Signpath as a small-cap, clinical-stage biotech focused on novel glioblastoma therapeutics with similar regulatory pathway considerations.
  • Kintara Therapeutics: Clinical-stage oncology company developing VAL-083 (dianhydrogalactitol) for glioblastoma. Comparable small-cap structure with similar Phase 2/3 development stage and indication focus.

Emerging players

  • Geron Corporation: Clinical-stage biotech that has pioneered novel oncology mechanisms (imetelstat) with similar small-cap, late-clinical-stage profile and dependence on a single platform technology.
  • INOVIO Pharmaceuticals: Clinical-stage biotech with DNA medicines including INO-5401 for glioblastoma. Comparable as a small-cap clinical-stage oncology company pursuing novel mechanisms in the same indication.
  • Curis: Clinical-stage oncology biotech developing small-molecule targeted therapies. Similar small-cap clinical-stage profile pursuing novel oncology mechanisms across multiple indications.

Broad incumbents

  • Bristol-Myers Squibb: Large oncology incumbent with checkpoint inhibitors (Opdivo) targeting PD-1/PD-L1 pathways relevant to LipoCurc's mechanism. Represents the broader immunotherapy landscape where LipoCurc's immunomodulatory claims would compete.
  • Novocure: Commercial-stage company with FDA-approved Tumor Treating Fields (Optune) for glioblastoma. Represents the established standard-of-care that LipoCurc would compete against in the same indication.

Others

  • Amgen: Large biopharmaceutical company explicitly cited by Signpath as the model for cancer supportive care (Neupogen). Represents the commercial reference for the supportive-care positioning of Signpath's CorreQT platform.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Signpath Pharma social profiles

Digital presence

Signpath Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Signpath Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Signpath Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Signpath Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Signpath Pharma

What does Signpath Pharma do?

Signpath Pharma is a clinical-stage pharmaceutical company that develops proprietary drug products built around two technology platforms. The first is LipoCurc, an intravenously administered liposomal curcumin formulation for cancer treatment (Phase 2 for glioblastoma). The second is the CorreQT platform, which creates cardiac-safe versions of existing drugs; its lead compound SPP4040 is an oral lipid-based drug designed to eliminate chemotherapy-induced cardiac arrhythmia and cardiac muscle damage.

Is Signpath Pharma a public or private company?

Signpath Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Signpath Pharma founded?

Signpath Pharma was founded in 2007. It employs 11 to 50 people.

Where is Signpath Pharma based?

Signpath Pharma is headquartered in Sandy, United States, in the North America region.

How does Signpath Pharma make money?

Three revenue lines are on record. LipoCurc (Liposomal Curcumin) is the primary driver. The others are correQT Platform Compounds and cancer Supportive Care.

Who are Signpath Pharma's main competitors?

Direct peers on record are Medicenna Therapeutics, Mustang Bio, Kazia Therapeutics and Kintara Therapeutics. Emerging players are Geron Corporation, INOVIO Pharmaceuticals and Curis. Broad incumbents are Bristol-Myers Squibb and Novocure. Amgen is listed as an others.

Does Signpath Pharma have an API?

No public API is recorded for Signpath Pharma.

What industry is Signpath Pharma in?

Signpath Pharma's product category is Clinical-stage Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals